Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
Under a Creative Commons license
open access
Abbreviations
AE
adverse event
Apo
apolipoprotein
BMI
body mass index
CV
cardiovascular
CVD
cardiovascular disease
EOT
end of treatment
EZE
ezetimibe
HbA1c
glycated hemoglobin A1c
HDL-C
high-density lipoprotein cholesterol
IQR
interquartile range
ITT
intent-to-treat
LDL-C
low-density lipoprotein cholesterol
LDLR
low-density lipoprotein receptors
LLN
lower limit of normal
Lp(a)
lipoprotein (a)
LS
least squares
mITT
modified intent-to-treat
NCEP-ATPIII
National Cholesterol Education Program Adult Treatment Panel III
NEC
not elsewhere classified
Non-HDL-C
non-high-density lipoprotein cholesterol
PCSK9
proprotein convertase subtilisin/kexin 9
Q2W
every 2 weeks
R
randomization
SAEs
serious adverse events
SC
subcutaneously
SCORE
systematic coronary risk estimation
SD
standard deviation
SE
standard error
TEAEs
treatment-emergent adverse events
TGs
triglycerides
ULN
upper limit of normal
Keywords
PCSK9
Monoclonal antibodies
Cholesterol-lowering drugs
Hypercholesterolemia
LDL-C
Alirocumab
Cited by (0)
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.